Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 5;8:4025. doi: 10.1038/s41598-018-22391-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2018

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Relationship between absolute blood cell counts and the clinical status of kidney transplant recipients. (A) Boxplots (25th, median, 75th percentile) of CD4⁺CXCR5⁺ absolute blood counts are shown for non-rejectors (NR), antibody-mediated rejectors (ABMR), T-cell mediated rejectors (TCMR), patients with recurrent autoimmune glomerulonephritis (GN) and patients with infection (n = 55 total). (B–D) Comparison of absolute CD4⁺CXCR5⁺, CD4⁺CD45RO⁺CXCR5⁺CCR7⁺ and CD4⁺CD45RO⁺CXCR5⁺CCR7^- blood counts in patients with ABMR. We compared blood cell counts among patients with no circulating DSAs, patients with DSAs against HLA class I, patients with DSAs against HLA class II and patients with DSAs against both HLA classes (n = 12 total). *p < 0.05; DSAs, donor-specific antibody.